# Seres Therapeutics

Seres Therapeutics' oral Firmicutes spore fraction, co-marketed with Nestle Health Science, was FDA-approved in April 2023 for recurrent CDI prevention — the first oral LBP, opening large-scale investment into the sector.

Source: https://en.bioecon.ru/companies/seres-therapeutics/
Updated: 2026-07-01

- Country: United States
- Ticker: NASDAQ:MCRB

## Technologies

- [Microbiome therapeutics (live biotherapeutic products)](https://en.bioecon.ru/technology/microbiome-therapeutics-lbps/)